Avidocin™ proteins have demonstrated in animal studies the potential for managing pathogenic bacterial threats, such as C. difficile and E. coli infections. Pylum is evaluating partnership opportunities with pharmaceutical partners for co-development of its existing pipeline of therapeutic agents for bacterial diseases, as well as partnerships with research institutions to pursue additional bacterial threats.
The highly selective nature of Avidocin proteins enables Pylum and its research partners to evaluate the potential of selectively subtracting specific bacteria from the gut and other microbiota. Each Avidocin protein can be tailored to a specific bacterial strain with no or very limited off-target effect. This approach can be used by investigators seeking to understand the role that a specific species or strain of bacteria may have in influencing broader areas of human health not currently considered to be infectious diseases, e.g. obesity, allergy, and autoimmunity.
Animal Health and Food Safety
Recognizing a potential application for precision antibacterial agents in animal health and food safety, Pylum has developed and partnered Purocin™ proteins for applications in food safety and is seeking partners to develop the animal health applications of this “antibiotic-free” treatment. These agents have the potential to reduce the use of broad spectrum antibiotics in the food supply.
To partner with us contact:
Office: (650) 243-2951
Fax: (650) 362-6585